Perspective Therapeutics (NYSE:CATX) Price Target Lowered to $16.00 at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX) had its target price lowered by Royal Bank of Canada from $25.00 to $16.00 in a research note released on Monday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other brokerages have also recently commented on CATX. UBS Group initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price for the company. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $24.00 to $5.00 in a research report on Monday. Oppenheimer reduced their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Truist Financial assumed coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price target for the company. Finally, Wedbush restated an “outperform” rating and set a $11.00 price objective (down from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.14.

Perspective Therapeutics Price Performance

NYSE:CATX opened at $4.12 on Monday. The stock has a 50 day simple moving average of $10.78 and a 200 day simple moving average of $12.32. Perspective Therapeutics has a 1-year low of $2.28 and a 1-year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million during the quarter. On average, research analysts forecast that Perspective Therapeutics will post -0.87 earnings per share for the current year.

Insider Buying and Selling

In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 14,500 shares of the company’s stock in a transaction on Monday, November 25th. The shares were purchased at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the purchase, the chief executive officer now owns 152,072 shares in the company, valued at $574,832.16. This represents a 10.54 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jonathan Robert Hunt acquired 12,829 shares of Perspective Therapeutics stock in a transaction dated Monday, November 25th. The shares were bought at an average cost of $3.82 per share, with a total value of $49,006.78. Following the transaction, the chief financial officer now owns 48,800 shares in the company, valued at approximately $186,416. This trade represents a 35.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 33,595 shares of company stock valued at $126,625 over the last quarter. Insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its stake in shares of Perspective Therapeutics by 8.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after buying an additional 1,672 shares in the last quarter. Sykon Capital LLC lifted its position in Perspective Therapeutics by 4.7% in the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after acquiring an additional 1,717 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Perspective Therapeutics by 5.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after purchasing an additional 3,211 shares during the last quarter. US Bancorp DE increased its holdings in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. Finally, nVerses Capital LLC purchased a new stake in shares of Perspective Therapeutics in the third quarter worth approximately $57,000. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.